NEUROCRINE BIOSCIENCES INC Contracts & Agreements
117 Contracts & Agreements
- Business Finance (15 contracts)
- Business Operations (10)
- Human Resources (18)
- Intellectual Property (2)
- Real Estate (5)
- Uncategorized (67)
- Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended and restated (Filed With SEC on August 1, 2023)
- Employment Agreement dated November 29, 2021 between the Company and Jude Onyia (Filed With SEC on August 4, 2022)
- Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended (Filed With SEC on August 4, 2022)
- Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, as amended (Filed With SEC on August 4, 2022)
- Commercial Lease dated February 8, 2022, by and between the Company and Gemdale Aperture Phase I, LLC (Filed With SEC on May 4, 2022)
- First Supplemental Indenture, dated as of December 22, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on February 11, 2022)
- Collaboration and License Agreement dated November 22, 2021 between Heptares Therapeutics Limited and the Company (Filed With SEC on February 11, 2022)
- Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, and Form of Restricted Stock Unit Award Grant... (Filed With SEC on February 11, 2022)
- Collaboration Agreement dated June 15, 2010, by and between Abbott International Luxembourg S.a.r.l. and the Company as amended on August 31, 2011 (Filed With SEC on May 5, 2021)
- First Amendment to Collaboration and License Agreement Dated August 31, 2011 between the Company and Abbott International Luxembourg S.a.r.l (Filed With SEC on May 5, 2021)
- Collaboration and License Agreement dated March 31, 2015 between Mitsubishi Tanabe Pharma Corporation and the Company (Filed With SEC on May 5, 2021)
- License Agreement dated February 9, 2017 between BIAL- Portela & CA, S.A. and the Company (Filed With SEC on May 5, 2021)
- Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (Filed With SEC on August 3, 2020)
- Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, and Form of Restricted Stock Unit Award Grant... (Filed With SEC on August 3, 2020)
- Description of Common Stock of the Company (Filed With SEC on February 7, 2020)
- Employment Agreement dated November 3, 2014 between the Company and Kyle Gano (Filed With SEC on February 7, 2020)
- Third Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P. dated August 7, 2019 (Filed With SEC on November 4, 2019)
- Amendment No. 1 to Collaboration and License Agreement dated June 14, 2019 between Voyager Therapeutics, Inc. and the Company (Filed With SEC on July 29, 2019)
- Employment Agreement dated January 8, 2018 between the Company and Eiry W. Roberts, M.D (Filed With SEC on July 29, 2019)
- Neurocrine Biosciences, Inc. Inducement Plan, as amended (Filed With SEC on February 13, 2018)
- Employment Agreement effective November 29, 2017 between the Company and Matt Abernethy (Filed With SEC on February 13, 2018)
- Form of Indemnity Agreement entered into with each of the Companys executive officers and directors (Filed With SEC on November 1, 2017)
- Amended and Restated Product Agreement dated June 27, 2017 by and between Patheon UK Limited and the Company (Filed With SEC on November 1, 2017)
- Second Amendment to Amended and Restated Lease dated October 12, 2017 between Kilroy Realty, L.P. and the Company (Filed With SEC on November 1, 2017)
- FIRST AMENDMENT TO AMENDED AND RESTATED LEASE (Filed With SEC on August 3, 2017)
- Amendment To Irrevocable Standby Letter Of Credit (Filed With SEC on August 3, 2017)
- NEUROCRINE BIOSCIENCES, INC. and U.S. BANKNATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 2, 2017 2.25%Convertible Senior Notes due 2024 TABLE OF CONTENTS (Filed With SEC on May 2, 2017)
- EMPLOYMENT AGREEMENT (Filed With SEC on February 14, 2017)
- EMPLOYMENT AGREEMENT (Filed With SEC on February 14, 2017)
- Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, CA 92130 (Filed With SEC on February 14, 2017)
- COLLABORATION AGREEMENT dated June 15, 2010 by and between AbbottInternational Luxembourg S.à r.l. and Neurocrine Biosciences, Inc. EXHIBIT INDEX (Filed With SEC on February 11, 2016)
- NEUROCRINE BIOSCIENCES, INC. INDUCEMENT PLAN ADOPTED: SEPTEMBER 15, 2014 AMENDED: OCTOBER 7, 2014 AMENDED: APRIL 29, 2015 (Filed With SEC on July 29, 2015)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on April 30, 2015)
- 6,944,000 Shares NEUROCRINE BIOSCIENCES, INC. Common Stock ($0.001par value per Share) UNDERWRITING AGREEMENT (Filed With SEC on February 19, 2015)
- Irrevocable Letter of Credit (Filed With SEC on February 9, 2015)
- NEUROCRINE BIOSCIENCES, INC. INDUCEMENT PLAN ADOPTED: SEPTEMBER 15, 2014 AMENDED: OCTOBER 7, 2014 (Filed With SEC on November 4, 2014)
- NEUROCRINE BIOSCIENCES, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:FEBRUARY 21, 2011 APPROVED BY THESTOCKHOLDERS: MAY 25, 2011 AMENDED BYTHE STOCKHOLDERS:... (Filed With SEC on August 6, 2014)
- 8,000,000 Shares NEUROCRINE BIOSCIENCES, INC. Common Stock ($0.001 parvalue per Share) UNDERWRITING AGREEMENT (Filed With SEC on February 27, 2014)
- NONEXCLUSIVE LICENSE AGREEMENT (Filed With SEC on July 26, 2013)
- NEUROCRINE BIOSCIENCES, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:FEBRUARY 21, 2011 APPROVED BY THESTOCKHOLDERS: MAY 25, 2011 AMENDED BYTHE STOCKHOLDERS:... (Filed With SEC on July 26, 2013)
- 9,500,000 Shares NEUROCRINE BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT (Filed With SEC on January 19, 2012)
- NEUROCRINE BIOSCIENCES, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:FEBRUARY 21, 2011 APPROVED BY THESTOCKHOLDERS: MAY 25, 2011 TERMINATION DATE:FEBRUARY 20,... (Filed With SEC on July 29, 2011)
- AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on February 10, 2011)
- Contract Number: 43031148 COLLABORATION AND LICENSE AGREEMENT Dated June 16, 2010 BY AND BETWEEN BOEHRINGER INGELHEIM INTERNATIONAL GmbH AND NEUROCRINE BIOSCIENCES, INC. TABLE OF... (Filed With SEC on July 29, 2010)
- COLLABORATION AGREEMENT dated June 15, 2010 by and between Abbott International Luxembourg S.à r.l. and Neurocrine Biosciences, Inc. (Filed With SEC on July 29, 2010)
- 9,100,000 Shares NEUROCRINE BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT (Filed With SEC on March 10, 2010)
- SECOND AMENDMENT TO LEASE (Filed With SEC on October 1, 2009)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 15, 2009)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on September 15, 2009)
- FINANCIAL STATEMENTS (Filed With SEC on July 30, 2009)
- Target Indication (Filed With SEC on February 4, 2009)
- Current assets (Filed With SEC on August 1, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Target Indication (Filed With SEC on February 11, 2008)
- Fifth Amendment to Purchase Agreement and Escrow Instructions dated December 3, 2007, among Neurocrine Biosciences, Inc., Science Park Center LLC and DMH Campus Investors, LLC (Filed With SEC on December 10, 2007)
- Fifth Amendment to Purchase Agreement and Escrow Instructions dated December 3, 2007, among Neurocrine Biosciences, Inc., Science Park Center LLC and DMH Campus Investors, LLC (Filed With SEC on December 10, 2007)
- Fifth Amendment to Purchase Agreement and Escrow Instructions dated December 3, 2007, among Neurocrine Biosciences, Inc., Science Park Center LLC and DMH Campus Investors, LLC (Filed With SEC on December 10, 2007)
- Current assets (Filed With SEC on November 2, 2007)
- Current assets (Filed With SEC on November 2, 2007)
- Current assets (Filed With SEC on November 2, 2007)
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (Filed With SEC on October 26, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on August 3, 2007)
- Neurocrine Biosciences, Inc. 2003 Incentive Stock Plan, as amended (Filed With SEC on May 31, 2007)
- Target Indication (Filed With SEC on February 9, 2007)
- On December 21, 2006, the Company announced that Wendell Wierenga, Ph.D, Executive Vice President of Research and Development has resigned from the Company. Dr. Wierenga will... (Filed With SEC on December 22, 2006)
- Current assets (Filed With SEC on November 9, 2006)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on September 19, 2006)
- EMPLOYMENT AGREEMENT (Filed With SEC on September 19, 2006)
- Current assets (Filed With SEC on May 3, 2006)
- Current assets (Filed With SEC on May 3, 2006)
- Amended agreement with GlaxoSmithKline dated February 7, 2006 (Filed With SEC on February 13, 2006)
- Target Indication (Filed With SEC on February 7, 2006)
- Exhibit No (Filed With SEC on January 19, 2006)
- Exhibit No (Filed With SEC on January 19, 2006)
- Description of Exhibit (Filed With SEC on November 1, 2005)
- Description of Exhibit (Filed With SEC on October 24, 2005)
- EXHIBITS. The following exhibits are (Filed With SEC on July 27, 2005)
- Description of Exhibit (Filed With SEC on June 24, 2005)
- Description of Exhibit (Filed With SEC on June 24, 2005)
- Target Indication (Filed With SEC on February 16, 2005)
- Target Indication (Filed With SEC on February 16, 2005)
- Current assets (Filed With SEC on August 9, 2004)
- Current assets (Filed With SEC on May 10, 2004)
- Legal Proceedings (Filed With SEC on March 15, 2004)
- Legal Proceedings (Filed With SEC on March 15, 2004)
- Legal Proceedings (Filed With SEC on March 15, 2004)
- Legal Proceedings (Filed With SEC on March 15, 2004)
- Legal Proceedings (Filed With SEC on March 15, 2004)
- FINANCIAL INFORMATION (Filed With SEC on November 7, 2003)
- FINANCIAL INFORMATION (Filed With SEC on November 7, 2003)
- FINANCIAL INFORMATION (Filed With SEC on November 7, 2003)
- FINANCIAL INFORMATION (Filed With SEC on November 7, 2003)
- FINANCIAL INFORMATION (Filed With SEC on November 7, 2003)
- FINANCIAL INFORMATION (Filed With SEC on November 7, 2003)
- Exhibit Number (Filed With SEC on September 12, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- FINANCIAL INFORMATION (Filed With SEC on August 8, 2003)
- Legal Proceedings (Filed With SEC on March 4, 2003)
- Legal Proceedings (Filed With SEC on March 4, 2003)
- Exhibit Number (Filed With SEC on December 20, 2002)
- Exhibit Number (Filed With SEC on December 20, 2002)